ArticleOncology letters2026
A novel inflammation and tumor marker-based prognostic score, neutrophil-lymphocyte ratio-C-reactive protein-Ca19-9, in metastatic gastric cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic gastric cancer is an aggressive malignancy characterized by poor survival rates and heterogeneous treatment outcomes. Reliable prognostic tools to identify patients who may benefit from systemic therapy remain limited. Therefore, there is a need for easily accessible and clinically applicable prognostic tools. The present single-center retrospective study included 70 patients with microsatellite-stable, HER2-negative metastatic gastric cancer who were treated with first-line fluoropyrimidine-based chemotherapy between 2020 and 2024. The present study aimed to develop and evaluate a novel composite prognostic score integrating systemic inflammation and tumor burden. The neutrophil-C-reactive protein (CRP)-CA19-9 (NCC) score was constructed based on baseline neutrophil-to-lymphocyte ratio (NLR ≥5), CRP >20 mg/l and CA19-9 levels (>90 U/ml). Patients were classified into low-risk (0-1) and high-risk (2-3) groups. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier and Cox regression methods, with internal validation performed by bootstrap resampling. The median OS for the entire cohort was 13.4 months. A high NCC score was associated with significantly shorter OS compared with a low NCC score (9.6 vs. 15.2 months; P=0.00065) and an increased risk of mortality (hazard ratio=2.59; 95% CI: 1.47-4.56). The median PFS was also shorter in the high-risk NCC group (9.2 vs. 10.1 months; P=0.04). The optimism-corrected C-index for OS was 0.60, indicating that the NCC score is a simple and practical prognostic tool for survival stratification with favorable discriminative performance compared with established prognostic indices in metastatic gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.